116563-00-9

Upstream product

• 133156-47-5 (4R,6S)-4-Benzyloxy-2-methoxy-6-trityloxymethyl-tetrahydro-pyran 
• 866088-08-6 C₁₆H₂₂O₅ 
• 106444-95-5 Dithiocarbonic acid O-((2R,3S,4S)-4-benzyloxy-6-methoxy-2-trityloxymethyl-tetrahydro-pyran-3-yl) ester S-methyl ester 
• 14241-58-8 (1R,3S,5S)-6,8-dioxabicyclo[3.2.1]octan-3-ol 
• 95641-15-9 1,6-anhydro-3-O-benzyl-2,4-dideoxy-β-D-threo-hexopyranoside 
• 32233-44-6 2-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]acetaldehyde 
• 50880-93-8 levoglucosan tritosylate 
• 67-56-1 methanol 
• 100-39-0 benzyl bromide 
• 87318-96-5 (S)-1-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-pent-4-en-2-ol 

Downstream Products

• 87318-95-4 (4S,6R)-4-Benzyloxy-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-tetrahydro-pyran-2-one 
• 866114-13-8 (2S,4R)-4-(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-carbaldehyde 
• 106732-01-8 (2S,4R)-4-(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-carbaldehyde 
• 112996-05-1 2,4-dideoxy-3,6-di-O-benzyl-α- and β-D-threo-hexopyranoses 
• 88096-46-2 (4S,6S)-4-benzyloxy-6-benzyloxymethyltetrahydropyran-2-one 
• 112996-03-9 methyl 2,4-dideoxy-3,6-di-O-benzyl-α-D-threo-hexopyranoside 
• 112996-03-9 methyl 2,4-dideoxy-3,6-di-O-benzyl-α- and β-D-threo-hexopyranoside 
• 87319-09-3 (4S,6R)-4-Benzyloxy-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2-((Z)-(3S,4R,5S)-4-hydroxy-3,5-dimethyl-hept-1-enyl)-tetrahydro-pyran-2-ol 
• 87319-08-2 (4S,6R)-4-Benzyloxy-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2-((3S,4R,5S)-4-hydroxy-3,5-dimethyl-hept-1-ynyl)-tetrahydro-pyran-2-ol 
• 87319-10-6 {2-[(2R,4S,6S,8R,9S)-4-Benzyloxy-8-((S)-sec-butyl)-9-methyl-1,7-dioxa-spiro[5.5]undec-10-en-2-yl]-ethoxy}-tert-butyl-diphenyl-silane 
• 87319-11-7 2-[(2R,4S,6S,8R,9S)-4-Benzyloxy-8-((S)-sec-butyl)-9-methyl-1,7-dioxa-spiro[5.5]undec-10-en-2-yl]-ethanol 

Relevant academic research and scientific papers

PROCESS AND INTERMEDIATE COMPOUNDS USEFUL IN THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN

There is provided a process for the preparation of a compound of formula (7): formula (7) wherein R1 represents an alkyl group; R2 represents an aryl group; R3 represents hydrogen, a protecting group or an alkyl group; and

Preparation of a Chiral Lactone from Leavoglucosan; a Key Intermediate for Synthesis of the Spiroacetal Moietes of the Avermectins and Milbemycins

A synthesis of two diprotected (4S,6S)-4-hydroxy-6-hudroxymethyltetrahydropyran-2-ones has been developed from laevoglucosan.Reaction of these lactones with a substituted chiral lithium acetylide followed by hydrogenation and acid-catalysed cyclisation led to formation of the spiroacetal moiety of milbemycin α1 and α3.The acetylene was prepared by resolution of racemic material obtained from reaction of lithium acetylide and cis-butene epoxide.Alternatively a stereocontrolled synthesis was developed from (S)-methyl-3-hydroxy-2-methylpropionate which involved 'chelation controlled' addition of lithium dimethylcuprate to the corresponding tetrahydropyranyloxy aldehyde.

Stereocontrolled Synthesis of the Spiro Ketal Unit of Avermectin B1a Aglycon

A stereocontrolled total synthesis of the 1,7-dioxaspiroundecene subunit of the avermectin B1a aglycon is presented based on the "chiron" approach which utilizes optically active starting materials.